Portage Biotech (NASDAQ:ALP) Insider Purchases $35,490.00 in Stock

Portage Biotech Inc. (NASDAQ:ALP) insider Fiorenzo Villani bought 7,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $35,490.00. Following the completion of the purchase, the insider directly owned 22,219 shares in the company, valued at approximately $112,650.33. The trade was a 46.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Portage Biotech Stock Performance

NASDAQ:ALP opened at $4.10 on Thursday. The business’s 50-day moving average price is $10.03 and its two-hundred day moving average price is $14.50. Portage Biotech Inc. has a twelve month low of $3.20 and a twelve month high of $690.00. The stock has a market cap of $6.35 million, a P/E ratio of -0.01 and a beta of 0.54. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.01.

Portage Biotech (NASDAQ:ALP) last issued its quarterly earnings data on Thursday, July 16th. The company reported $23.75 EPS for the quarter. The business had revenue of $0.05 million for the quarter. As a group, equities analysts predict that Portage Biotech Inc. will post -14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ALP. Wall Street Zen raised shares of Portage Biotech to a “hold” rating in a report on Saturday, September 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Portage Biotech in a report on Friday, July 24th. HC Wainwright started coverage on shares of Portage Biotech in a research report on Monday, August 17th. They issued a “neutral” rating and a $12.50 target price for the company. Finally, Zacks Research raised Portage Biotech to a “hold” rating in a research note on Tuesday, August 18th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $12.50.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.